On December 28, 2023 ChemDiv, a global leader in drug discovery solutions, reported a strategic collaboration with the University of Texas Medical Branch (UTMB) to facilitate the expansion of its inventory and advance the institution’s High-throughput Screening (HTS) research programs (Press release, ChemDiv, DEC 28, 2023, View Source [SID1234638844]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ChemDiv’s comprehensive suite of fully integrated Research & Development services offers UTMB unparalleled support in its pursuit of groundbreaking medical research. By leveraging ChemDiv’s 32 years of experience, advanced capabilities, and a seasoned team of experts, UTMB aims to push the boundaries of medical research and translate discoveries into tangible treatments for pressing medical needs.

"At ChemDiv, we are dedicated to catalyzing pioneering research, and our collaboration with UTMB exemplifies our commitment to advancing healthcare globally," said Bill Farley, CEO of ChemDiv. "Our team’s expertise and cutting-edge resources are poised to significantly augment UTMB’s HTS research center, accelerating the discovery of novel therapeutic solutions."